DCF Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

DCF Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,500	Closed	-$10K	–	102
2025 Q2	$10K	Sell	2,500 -2,500	-50%	-$9.1K	﹤0.01%	84
2025 Q1	$15.9K	Buy	+5,000	New	+$23.6K	0.01%	85

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

DCF Advisers's CRVS Position: Q2 2026 in Review

DCF Advisers held its Corvus Pharmaceuticals (CRVS) position steady in Q2 2026 at 637,500 shares worth $9.52M. The position accounts for 1.68% of the portfolio, ranked #9.

DCF Advisers first reported a position in CRVS in Q1 2025 and has held it in 5 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

DCF Advisers held 637,500 shares of Corvus Pharmaceuticals worth $9.52M as of Q2 2026.
DCF Advisers left its Corvus Pharmaceuticals share count unchanged in Q2 2026.
Corvus Pharmaceuticals made up 1.68% of DCF Advisers's portfolio in Q2 2026, its #9 holding.
DCF Advisers first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.